Plerixafor

PHARMACOKINETICS

Absorption

Plerixafor is rapidly absorbed after subcutaneous administration, reaching peak plasma concentrations within about 30–60 minutes. Its absolute bioavailability is high (around 80–90%), meaning most of the administered dose enters systemic circulation.

Distribution

Plerixafor has a moderate volume of distribution, indicating it is largely confined to the extracellular fluid rather than extensively distributing into tissues. It shows low to moderate plasma protein binding, and does not significantly accumulate in red blood cells, which helps it remain readily available in the circulation to mobilize hematopoietic stem cells from the bone marrow into peripheral blood.

Metabolism

Plerixafor undergoes minimal metabolism in the body. It is not significantly processed by hepatic cytochrome P450 enzymes, which reduces the risk of drug–drug interactions related to liver metabolism. The drug remains largely unchanged in systemic circulation before being eliminated.

Elimination

Plerixafor is primarily eliminated unchanged through the kidneys via renal excretion. A large proportion of the administered dose is recovered in urine, indicating that renal clearance is the main route of removal from the body. Its elimination half-life is relatively short, typically around 3–5 hours, so dosing is timed to achieve effective stem cell mobilization before autologous collection procedures.

PHARMACODYNAMICS

Plerixafor is a reversible CXCR4 chemokine receptor antagonist that blocks the CXCR4–CXCL12 interaction in the bone marrow. This disruption releases hematopoietic stem cells into the bloodstream, increasing circulating CD34+ cells. When used with G-CSF, it produces a strong, rapid, and short-lived mobilization effect that peaks within hours and is used to support stem cell collection for transplantation.

ADMINISTRATION

Plerixafor is administered as a subcutaneous injection, usually in combination with granulocyte-colony stimulating factor (G-CSF). It is given about 11 hours before stem cell collection (apheresis), typically in the evening prior to the procedure, to ensure peak mobilization of hematopoietic stem cells into the bloodstream during collection the following morning.

DOSAGE AND STRENGTH

Plerixafor is supplied as a sterile solution for subcutaneous injection with a standard concentration of 24 mg/1.2 mL (20 mg/mL) in a single-use vial. The usual recommended dose is 0.24 mg/kg body weight, administered once daily in combination with G-CSF. In patients with renal impairment (especially creatinine clearance ≤50 mL/min), the dose is reduced to0.16 mg/kg. It is typically given about 11 hours before the start of stem cell collection (apheresis).

DRUG INTERACTIONS

Plerixafor has a low potential for drug–drug interactions because it is not significantly metabolized by cytochrome P450 enzymes and does not inhibit or induce major metabolic pathways. However, caution is advised when used with drugs that affect renal function, as plerixafor is primarily eliminated unchanged through the kidneys. No major clinically significant interactions have been consistently reported, but it is commonly used in combination with granulocyte-colony stimulating factor (G-CSF), which enhances its stem cell mobilizing effect.

FOOD INTERACTIONS

Plerixafor has no known clinically significant food interactions. It is administered as a subcutaneous injection, so food does not affect its absorption or overall effectiveness. Patients do not need to follow any specific dietary restrictions when receiving the drug, although it is typically used in a controlled clinical setting alongside granulocyte-colony stimulating factor (G-CSF) for stem cell mobilization.

CONTRAINDICATIONS

Plerixafor is contraindicated in patients with a known hypersensitivity to plerixafor or any of its components. It should also be avoided in individuals who have had a severe allergic reaction to the drug in the past. Additionally, caution is required in patients with leukemia, as mobilization of malignant cells into the bloodstream may occur in some cases.

SIDE EFFECTS

• Abdominal discomfort 

• Injection-site reactions (redness, swelling, pain) 

• Headache 

• Dizziness 

• Fatigue 

• Muscle and joint pain 

• Increased white blood cell count (transient)

OVER DOSAGE

Plerixafor overdose may lead to excessive mobilization of hematopoietic stem cells, resulting in leukocytosis. Patients may experience symptoms such as nausea, diarrhea, abdominal discomfort, headache, dizziness, or fatigue. There is no specific antidote, so treatment is supportive with careful monitoring of blood counts and clinical status.

TOXICITY

Plerixafor toxicity is generally related to exaggerated pharmacologic effects rather than direct organ damage. The most notable toxic effect is marked leukocytosis due to excessive mobilization of hematopoietic stem cells into the bloodstream. Patients may also develop gastrointestinal symptoms (nausea, diarrhea, abdominal pain), neurological effects such as dizziness or headache, and fatigue.